by Kevin Robb | Aug 22, 2024
Last month, the U.S. Food and Drug Administration (FDA) agreed to formally review a revised Biologics License Application (BLA) from Mesoblast for their mesenchymal stromal cell (MSC) product, remestemcel-L. The submission represents the third attempt by the company...
by Medicine by Design | Aug 6, 2024
CCRM, the publisher of Signals, has enhanced its long-standing relationship with the University of Toronto’s Medicine by Design through a new strategic alliance. This profile is one in a series of profiles that feature “people” of Medicine by Design. Some minor edits...
by Lyla El-Fayomi | Jun 18, 2024
“Regenerative medicine news under the microscope” is a monthly feature highlighting a selection of impactful research findings and headlines across the many subfields of regenerative medicine. Throughout the past month, I’ve spotted some notable trends emerging in the...
by Krystal Jacques | Apr 11, 2024
In current organoid technologies, human pluripotent stem cells are guided to differentiate into 3D structures that resemble the corresponding human in-vivo organ, which allows researchers the opportunity to study the organ’s specific cells and function. However,...
by Stacey Johnson | Feb 23, 2024
As a fair-skinned, freckled person (my mom says she painted them on me while I slept), and one who has a family history of skin cancers and melanoma, the news on February 19 that Iovance Biotherapeutics’ AMTAGVITM received U.S. Food and Drug Administration (FDA)...
Comments